LexisNexis® Legal Newsroom
NYC Jury: Novartis Discriminated Against Women

NEW YORK - (AP) A jury has decided that the drug company Novartis AG engaged in a pattern of discrimination against women, paying them less than men and treating pregnant women unfavorably. The verdict was returned Monday in Manhattan federal court. The jury awarded several million dollars total...

Novartis Hit With $250M Punitive Damage Award

NEW YORK - (AP) A jury that found drug company Novartis discriminated against women by paying them less than men, promoting fewer of them and allowing a hostile workplace awarded $250 million in punitive damages on Wednesday. The same jury concluded Monday that Novartis Pharmaceuticals Corp. had discriminated...

Novartis To Pay $422.5M In Marketing, Kickbacks Case

PHILADELPHIA - (AP) Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials announced Thursday. The company agreed to plead guilty to distribution...

$12.8M Verdict For Jaw Injury In Aredia/Zometa Case To Be Reduced To $1.14M

WINSTON-SALEM, N.C. - (Mealey's) A North Carolina federal jury on Nov. 22 awarded $12,887,001 in an Aredia/Zometa jaw injury case, a verdict that will be reduced to $1,148,001 by North Carolina's limit on punitive damages ( Herbert Fussman, et al. v. Novartis Pharmaceuticals Corporation , No...

Novartis Wins Defense Verdict In Zometa Jaw Injury Trial

BROOKLYN, N.Y. (Mealey's) A New York federal jury in the first federal Zometa trial found May 25 that the plaintiff did not prove by a preponderance of evidence that the Novartis Pharmaceuticals Corp. drug caused a decedent's osteonecrosis of the jaw (ONJ) ( Karlene Hogan, et al. v. Novartis...

Jury Awards Plaintiff $10.4 Million For Injuries, Punitive Damages Linked To Novartis' Zometa

CENTRAL ISLIP, N.Y. - (Mealey's) A New York federal jury on Nov. 2 found Novartis Pharmaceuticals Corp. liable for a woman's osteonecrosis of the jaw (ONJ) and awarded her $10.45 million, according to the parties ( Barbara Davids v. Novartis Pharmaceuticals Corporation , No. 2:06-431, E.D. N...

Another Specialty Pharmacy Settles Exjade False Claims Allegations For $45 Million

NEW YORK —(Mealey’s) Specialty pharmacy Accredo Health Group Inc. on April 30 agreed to pay $45 million to settle a whistle-blower’s allegations that its efforts to push prescriptions for the iron chelation drug Exjade resulted in false claims being submitted to federal health care...